Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey
Autore:
Coiffier, B; Guastalla, JP; Pujade-Lauraine, E; Bastit, P;
Indirizzi:
CH Lyon Sud, Dept Hematol, Hospices Civils Lyon, F-69495 Pierre Benite, France CH Lyon Sud Pierre Benite France F-69495 , F-69495 Pierre Benite, France Ctr Reg Lutte Canc, Lyon, France Ctr Reg Lutte Canc Lyon FranceCtr Reg Lutte Canc, Lyon, France Hop Hotel Dieu, Serv Oncol, Paris, France Hop Hotel Dieu Paris FranceHop Hotel Dieu, Serv Oncol, Paris, France Ctr Henri Becquerel, F-76038 Rouen, France Ctr Henri Becquerel Rouen France F-76038 ecquerel, F-76038 Rouen, France
Titolo Testata:
EUROPEAN JOURNAL OF CANCER
fascicolo: 13, volume: 37, anno: 2001,
pagine: 1617 - 1623
SICI:
0959-8049(200109)37:13<1617:PCAIPR>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT-HUMAN-ERYTHROPOIETIN; QUALITY-OF-LIFE; INDUCED ANEMIA; COMMUNITY ONCOLOGY; BLOOD-TRANSFUSION; EPOETIN-ALPHA; DOUBLE-BLIND; MALIGNANCIES; THERAPY;
Keywords:
anaemia; non-platinum chemotherapy; risk factors; epoetin alfa; erythropoietin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Coiffier, B CH Lyon Sud, Dept Hematol, Hospices Civils Lyon, F-69495 Pierre Benite, France CH Lyon Sud Pierre Benite France F-69495 erre Benite, France
Citazione:
B. Coiffier et al., "Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey", EUR J CANC, 37(13), 2001, pp. 1617-1623

Abstract

A 2-year retrospective chart survey of 1064 patients with colorectal, breast, lung or ovarian cancer, Hodgkin's disease, or non-Hodgkin's lymphoma was conducted at 24 centres in France to determine the prevalence of anaemia (haemoglobin (Hb) levels less than or equal to 120 g/l) and need for transfusion in patients who received non-platinum-based chemotherapy for more than three cycles or 3 months. Baseline Hb levels documented anaemia in 37.1 %of patients (all tumour types). By cycle 3, the prevalence of anemia increased to 54.1 % of patients and remained over 50 % at cycle 4. At some time during chemotherapy 14.5 % of patients were transfused. Predictive risk factors for anaemia requiring transfusion included low baseline Hb, decrease in Hb during the first month of chemotherapy, primary tumour site, prior blood transfusions and duration of chemotherapy. By early identification of patients at the highest risk of developing anaemia, interventions such as epoetin alfa can be employed to reduce or eliminate the need for transfusions. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 23:21:44